Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European Post-Authorization Safety Study (PASS) Study of SCENESSE in Adult Erythropoietic Protoporphyria Patients

Trial Profile

European Post-Authorization Safety Study (PASS) Study of SCENESSE in Adult Erythropoietic Protoporphyria Patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Erythropoietic protoporphyria
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Sep 2019 According to a Clinuvel Pharmaceuticals media release, long-term safety and effectiveness data from the treatment of erythropoietic protoporphyria (EPP) patients with SCENESSE (afamelanotide 16mg), from this study will be presented this week at the International Congress on Porphyrins and Porphyrias (ICPP) in Milan, Italy.
    • 29 Mar 2019 According to a Clinuvel Pharmaceuticals media release, Clinicians and medical staff from a number of EPP expert centres will participate in the full day meetings focused on results from this ongoing study.
    • 05 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top